Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is dedicated to developing treatments for cardiometabolic, pulmonary, liver, and neuromuscular diseases. The company utilizes its proprietary TRiM™ platform to deliver targeted RNAi molecules, aiming to address the underlying genetic causes of these conditions. Arrowhead has set a goal to have 20 individual products in clinical trials or on the market by 2025. Currently, the company has several promising candidates in various stages of clinical trials, including Plozasiran (ARO-APOC3) in Phase 3 for severe hypertriglyceridemia, Olpasiran (licensed to Amgen) in Phase 3 for cardiovascular disease, and Fazirsiran (ARO-AAT) in Phase 3 for alpha-1 liver disease. Other notable candidates include ARO-RAGE in Phase 1 for inflammatory pulmonary diseases, ARO-C3 in Phase 1/2a for complement-mediated renal disease, ARO-DUX4 in Phase 1/2a for facioscapulohumeral muscular dystrophy type 1, ARO-DM1 in Phase 1/2a for myotonic dystrophy type 1, ARO-HBV in Phase 2 for hepatitis B, Zodasiran (ARO-ANG3) in Phase 2 for dyslipidemia, ARO-MUC5AC in Phase 1 for muco-obstructive lung diseases, and GSK4532990 (ARO-HSD) in Phase 2 for NASH. Arrowhead’s research and development operations are based in Madison, WI, and San Diego, CA, with corporate headquarters in Pasadena, CA. The company actively engages in collaboration and licensing agreements with leading biotechnology and pharmaceutical companies to advance its pipeline, which includes treatments for severe hypertriglyceridemia, dyslipidemia, inflammatory pulmonary diseases, and cardiovascular disease.